Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Assets (2021 - 2025)

Prime Medicine's Current Assets history spans 5 years, with the latest figure at $181.3 million for Q4 2025.

  • For Q4 2025, Current Assets fell 14.44% year-over-year to $181.3 million; the TTM value through Dec 2025 reached $181.3 million, down 14.44%, while the annual FY2025 figure was $181.3 million, 14.44% down from the prior year.
  • Current Assets reached $181.3 million in Q4 2025 per PRME's latest filing, down from $231.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $296.6 million in Q4 2022 to a low of $121.3 million in Q2 2025.
  • Average Current Assets over 5 years is $204.0 million, with a median of $211.9 million recorded in 2024.
  • Peak YoY movement for Current Assets: tumbled 51.8% in 2023, then skyrocketed 48.2% in 2024.
  • A 5-year view of Current Assets shows it stood at $270.6 million in 2021, then rose by 9.62% to $296.6 million in 2022, then crashed by 51.8% to $143.0 million in 2023, then surged by 48.2% to $211.9 million in 2024, then fell by 14.44% to $181.3 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Current Assets are $181.3 million (Q4 2025), $231.4 million (Q3 2025), and $121.3 million (Q2 2025).